Jinbiao Zhan

Dr. Jinbiao Zhan


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
MKMuhammad Kalim
Muhammad Kalim
JCJie Chen
Jie Chen
SWShenghao Wang
Shenghao Wang
CLCaiyao Lin
Caiyao Lin
SUSaif Ullah
Saif Ullah
JZJinbiao Zhan
Jinbiao Zhan
Antibody–drug conjugate (ADC) is a milestone in targeted cancer therapy that comprises of monoclonal antibodies chemically linked to cytotoxic drugs. Internalization of ADC takes place via clathrin-mediated endocytosis, caveolae-mediated endocytosis, and pinocytosis. Conjugation strategies, endocytosis and intracellular trafficking optimization, linkers, and drugs chemistry present a great challenge for researchers to eradicate tumor cells successfully. This inventiveness of endocytosis and intracellular trafficking has given consi­derable momentum recently to develop specific antibodies and ADCs to treat cancer cells. It is significantly advantageous to emphasize the endocytosis and intracellular trafficking pathways efficiently and to design potent engineered conjugates and biological entities to boost efficient therapies enormously for cancer treatment. Current studies illustrate endocytosis and intracellular trafficking of ADC, protein, and linker strategies in unloading and also concisely evaluate practically applicable ADCs.

1 July 2015 in Biomaterials
Verified
Journal Article
Closed access
QLQingpo Li
Qingpo Li
QTQin Tang
Qin Tang
PZPeizun Zhang
Peizun Zhang
ZWZuhua Wang
Zuhua Wang
TZTiantian Zhao
Tiantian Zhao
Jian YouJian You
Jian You

1 December 2021 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
KLKeying Liang
Keying Liang
SMShengsheng Mei
Shengsheng Mei
XGXiangzheng Gao
Xiangzheng Gao
SPShanshan Peng
Shanshan Peng
JZJinbiao Zhan
Jinbiao Zhan
Purpose: T-DM1 is an antibody–drug conjugate (ADC) consisting of trastuzumab and DM1 linked together. T-DM1 binds to human epidermal growth factor receptor-2 (HER2) in tumors and then triggers the endocytosis of T-DM1 and release of payload. Therefore, endocytosis efficacy is considered as a critical step for the initiation of T-DM1 therapy; however, the endocytosis mechanism of T-DM1 remains poorly understood. Meanwhile, HER2 is regarded as an internalization-resistant receptor, which hinders the endocytosis and effectiveness of T-DM1. The present study is to explore the T-DM1 endocytosis pathway, which may provide insights into the internalization mechanism of ADCs and help to improve efficacy. Methods: Confocal microscopy and flow cytometry were used to analyse T-DM1 intracellular trafficking and endocytosis efficiency, while Western blot assay was performed to detect T-DM1 degradation. Results: We found that intracellular T-DM1 was increased to 50% within 12 h. T-DM1 was colocalized with cholera toxin B (CTxB), a lipid raft marker, within 2 h and then degraded in lysosome. Upon overexpression of caveolin-1 (CAV-1) and utilization of caveolae/lipid-raft disruptors, we found that temporal CAV-1 upregulation significantly facilitated T-DM1 endocytosis and degradation, whereas nystatin and lovastatin disrupted caveolae/lipid-raft structure and inhibited T-DM1 degradation. We demonstrate that T-DM1 internalizes through the lipid raft-mediated endocytosis in a CAV-1 dependent manner, rather than through the clathrin-mediated endocytosis in HER2-positive cancer cells. Conclusion: Our findings suggest that modulation of the caveolae/lipid-raft mediated endocytosis may be a possible option for improving the clinical therapeutic effect of T-DM1 because it plays a key role in regulating T-DM1 internalization.

30 June 2021 in Preparative Biochemistry & Biotechnology
Verified
Journal Article
Closed access
XGXiangzheng Gao
Xiangzheng Gao
SPShanshan Peng
Shanshan Peng
SMShengsheng Mei
Shengsheng Mei
KLKeying Liang
Keying Liang
MKMuhammad Saleem Iqbal Khan
Muhammad Saleem Iqbal Khan
JZJinbiao Zhan
Jinbiao Zhan
The receptor binding domain (RBD) of SARS-CoV-2 is located in the C-terminal of S1 subunit of the spike (S) protein which is responsible for recognizing and binding to the angiotensin-converting enzyme 2 (ACE2) receptor. The DNA encoding the SARS-CoV-2 RBD was inserted into pET-28a (+) to construct expression plasmid pET-28a (+)/RBD. The desired RBD protein was produced in E. coli Rosetta (DE) and purified by a Ni-NTA column. The recombinant RBD was analyzed by SDS-PAGE and Western blot. The flow cytometry analysis indicated that the recombinant RBD is capable of binding to human ACE2 (hACE2) in the ACE2-overexpressed HEK293A-hACE2 cells. Our results demonstrated that recombinant RBD expressed in E. coli Rosetta (DE) strain has bioactivities and can be used as an antigen for diagnosis and as a tool for the development of novel anti-viral drugs against SASR-CoV-2.

12 March 2020 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
MKMuhammad Kalim
Muhammad Kalim
MKMuhammad Saleem Iqbal Khan
Muhammad Saleem Iqbal Khan
JZJinbiao Zhan
Jinbiao Zhan

1 October 2017 in Immunology Letters
Verified
Journal Article
Closed access
MKMuhammad Kalim
Muhammad Kalim
JCJie Chen
Jie Chen
SWShenghao Wang
Shenghao Wang
CLCaiyao Lin
Caiyao Lin
SUSaif Ullah
Saif Ullah
JZJinbiao Zhan
Jinbiao Zhan